Search

Your search keyword '"Wu, Shimin"' showing total 546 results
Start Over Author "Wu, Shimin"
546 results on '"Wu, Shimin"'

105. Progress and research at the Shanghai EBIT (1)

Author

Hu, Wei, Fu, Yunqing, Gong, Peirong, Yao, Ke, Lu, Di, Chen, Weidong, Liu, Yong, Yang, Yang, Xiao, Jun, Wu, Shimin, Geng, Zhixian, Huang, Min, Zhang, Xuemei, Hutton, Roger, Liljeby, Leif, He, Mianhong, and Zou, Yaming

Subjects
Physics
Abstract

Abstract: In this report, a brief description of the current progress at the Shanghai EBIT project is presented. This is followed by a short discussion of the measurement of various [...]

Published
2008

126. RETRACTED ARTICLE: Long Non-Coding RNA EGOT Promotes the Malignant Phenotypes of Hepatocellular Carcinoma Cells and Increases the Expression of HMGA2 via Down-Regulating miR-33a-5p

Author

Wu,Shimin, Ai,Hongwu, Zhang,Kehui, Yun,Hao, Xie,Fei, Wu,Shimin, Ai,Hongwu, Zhang,Kehui, Yun,Hao, and Xie,Fei

Abstract

This paper has been retracted.Wu S, Ai H, Zhang K, Yun H, Xie F. Onco Targets Ther. 2019;12:11623‒11635. The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 2, 3 and 6. Specifically, Figure 2E, si-RNA-NC appears to have been duplicated with the same image for Figure 6G, EGOT/miR-33a-5p which has been rotated. Figure 2E, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 3F, EGOT which has been rotated. Figure 2F, si-RNA-NC appears to have been duplicated with the same image for Figure 3E, lncRNA-NC which has been rotated. Figure 2F, si-RNA-NC appears to have been duplicated with the same image for Figure 6G, NC which has been rotated. Figure 2F, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 3F, lncRNA-NC. Figure 2F, siRNA-EGOT-1 appears to have been duplicated with the same image for Figure 6H, EGOT/miR-33a-5p which has been rotated. Figure 3E, lncRNA-NC appears to have been duplicated with the same image for Figure 6G, NC which has been rotated. Figure 3F, lncRNA-NC appears to have been duplicated with the same image for Figure 6H, EGOT/miR-33a-5p. The authors did not respond to our queries and the Editor requested to retract the article and the authors were notified of this. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Published
2019

139. Advanced pneumonic type of lung adenocarcinoma: survival predictors and treatment efficacy of the tumor

Author

Zong, Qiu, Zhu, Feng, Wu, Shimin, Peng, Li, Mou, Yong, Miao, Kang, Wang, Qi, Zhao, Jianping, Xu, Yongjian, and Zhou, Min

Abstract

Purpose: To retrospectively explore the survival predictors and treatment efficacy of advanced pneumonic-type lung adenocarcinoma (P-ADC).Methods: Retrospective analysis of clinical data and survival follow-up was undertaken on 41 patients with advanced P-ADC from January 1, 2009, to April 30, 2019. Analysis on tumor biomarkers such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and the cytokeratin-19-fragment (Cyfra21-1) were undertaken. The patients in this study were divided into three groups based on usage of tyrosine kinase inhibitor (TKI): TKI therapy group (including combination with chemotherapy), non-TKI therapy group (chemotherapy alone), and palliative care group.Results: More than half of the patients had higher levels of tumor biomarkers and the incidence of NSE was highest (81.8%), followed by CEA (74.4%) and Cyfra21-1 (74.1%). All patients had abnormal findings on chest computed tomography and with adenocarcinoma pathology. The overall survival (OS) time was 10.4 months in TKI group, 8.8 months in the non-TKI group, and 2.1 months in the palliative care group. Patients with higher level of serum Cyfra21-1 had insignificantly shorter survival time compared to those with normal Cyfra21-1 (p= 0.067). TKI therapy and non-TKI therapy provided a better prognosis prediction compared to palliative care. TKI therapy improved prognosis compared to non-TKI therapy. The comprehensive based TKI therapy provided improved OS vs the non-TKI therapy.Conclusion: TKI-based therapy could improve the prognosis and OS for advanced P-ADC. This study recommends the analysis of EGFRmutations for all patients with advanced P-ADC.

Published
2021
Full Text
View/download PDF

146. Halogenated polycyclic aromatic hydrocarbons in Chinese traditional sausages with high salt: Profiles in market samples and formation during home cooking.

Author

Li, Wei and Wu, Shimin

Subjects
*SAUSAGES, *FOOD safety
Abstract

[Display omitted] • The TEQ concentrations of PAH42 in two smoked sausages exceeded the BaP limit. • Smoked sausages exhibited significantly higher PAH levels than non-smoked sausages. • Chlorinated PAHs can be generated during sausage home cooking. • Boiling, steaming, and baking at 180 °C do not result in increased PAHs in foods. • Overcooking (baking at 220 °C) lead to an exaggerated increase (148%–462%) in PAHs. Halogenated polycyclic aromatic hydrocarbons (XPAHs) are likely to be generated by the reaction between polycyclic aromatic hydrocarbons (PAHs) and halide ions and therefore pose a great threat to high salt food safety. The aim is to explore the profiles of PAHs/XPAHs in market sausages and their formation during home cooking. Concentrations of PAH24 and XPAH18 in 36 market samples were 5.18–408.52 μg/kg and 0.05–0.41 μg/kg, respectively. Smoked sausages exhibited significantly higher concentrations of PAHs than non-smoked sausages. While ready-to-eat sausages presented notably higher XPAH levels than raw sausages. Furthermore, overcooking, such as baking at 220 °C, could result in an exaggerated increase in PAHs. Meanwhile, the increased chlorinated PAH levels after cooking indicated the unintentional formation of XPAHs during sausage cooking. Based on the ILCR model, the intake of 12.7 g/d for males and 10.8 g/d for females is the maximum threshold to achieve negligible risk levels (10−6). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results